Outcomes of Vdpace for Relapsed/Refractory Multiple Myeloma in the Era of Daratumumab Based Therapy

被引：0

作者：

Venkatesh, Priyanka ^{[1
,2
]}

Khasawneh, Ghena ^{[1
,3
]}

Hashmi, Hamza ^{[1
,4
]}

Alkharabsheh, Omar ^{[1
,5
]}

Paul, Barry ^{[1
,6
]}

Skikne, Barry S. ^{[1
,7
]}

Mahmoudjafari, Zahra ^{[1
,7
]}

Ahmed, Nausheen ^{[1
,7
]}

Abdallah, Al-Ola ^{[1
,7
]}

Atrash, Shebli ^{[1
,6
]}

机构：

[1] US Myeloma Innovat Res Collaborat USMIRC, Kansas City, KS USA

[2] Univ Kansas, Internal Med, Med Ctr, Kansas City, KS USA

[3] Jordan Univ Sci & Technol, Irbid, Jordan

[4] Med Univ South Carolina, Hollings Canc Ctr, Charleston, SC USA

[5] Univ S Alabama, Mobile, AL USA

[6] Atrium Hlth, Levine Canc Inst, Plasma Cell Disorders Sect, Dept Hematol Oncol & Blood Disorders, Charlotte, NC USA

[7] Univ Kansas, Div Hematol Malignancies & Cellular Therapeut, Med Ctr, Westwood, KS USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-188117

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[1] Outcomes of VDPACE with Immunomodulator Agent as a Salvage Therapy for Relapsed/Refractory Multiple Myeloma
Abdallah, Al-Ola
Shune, Leyla
Hochard, Erica
Dunavin, Neil
Mahmoudjafar, Zahra
Ganguly, Siddhartha
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S247 - S247
[2] Outcomes of VDPACE with an immunomodulatory agent as a salvage therapy in relapsed/refractory multiple myeloma with extramedullary disease
Abdallah, Al-Ola
Mohyuddin, Ghulam Rehman
Ahmed, Nausheen
Mohan, Meera
Cui, Wei
Shune, Leyla
Mahmoudjafari, Zahra
McGuirk, Joseph
Ganguly, Siddhartha
Atrash, Shebli
EJHAEM, 2021, 2 (04): : 757 - 764
[3] Outcomes of Vdpace with Immunomodulator Treatment in Initial and Relapsed/Refractory Multiple Myeloma in a Single Center
Abdallah, Al-Ola
McGuirk, Joseph P.
Shune, Leyla
Hochard, Erica
Dunavin, Neil
Mahmoudjafari, Zahra
Ganguly, Siddhartha
BLOOD, 2017, 130
[4] Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma
Blair, Hannah A.
DRUGS, 2017, 77 (18) : 2013 - 2024
[5] Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma
Hannah A. Blair
Drugs, 2017, 77 : 2013 - 2024
[6] Outcomes of VDPACE with an Immunomodulatory Agent (IMiD) as a Salvage Therapy in Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD)
Abdallah, Al-Ola
Atrash, Shebli
Mahmoudjafari, Zahra
McGuirk, Joseph
Ganguly, Siddhartha
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S302 - S303
[7] Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myeloma
Ziccheddu, Bachisio
Giannotta, Claudia
D'Agostino, Mattia
Bertuglia, Giuseppe
Saraci, Elona
Oliva, Stefania
Genuardi, Elisa
Papadimitriou, Marios
Diamond, Benjamin
Corradini, Paolo
Coffey, David
Landgren, Ola
Bolli, Niccolo
Bruno, Benedetto
Boccadoro, Mario
Massaia, Massimo
Maura, Francesco
Larocca, Alessandra
BLOOD CANCER JOURNAL, 2024, 14 (01):
[8] Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma
Usmani, Saad Z.
Nahi, Hareth
Mateos, Maria-Victoria
van de Donk, Niels W. C. J.
Chari, Ajai
Kaufman, Jonathan L.
Moreau, Philippe
Oriol, Albert
Plesner, Torben
Benboubker, Lotfi
Hellemans, Peter
Masterson, Tara
Clemens, Pamela L.
Luo, Man
Liu, Kevin
San-Miguel, Jesus
BLOOD, 2019, 134 (08) : 668 - 677
[9] Correction to: Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma
Hannah A. Blair
Drugs, 2018, 78 : 397 - 397
[10] The efficacy and safety of daratumumab in relapsed and refractory multiple myeloma
贾亚静
China Medical Abstracts(Internal Medicine), 2020, 37 (03) : 189 - 189

← 1 2 3 4 5 →